Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR (T1EV34) Stock Price & Analysis

T1EV34 Stock Chart & Stats

$106.80$0.00(0.00%)

At close: Oct 30

Day’s Range: $106.80 - $114.40
52-Week Range: $18.00 - $114.40
Previous Close: $106.80
Volume: N/A
Average Volume (3M): 32
Market Cap: BRL 258.04B
Enterprise Value: N/A
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): ―
Beta: -0.19
Next Earnings: Nov 03, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR News

Teva price target raised to $47 from $42 at Barclays

Barclays analyst Glen Santangelo raised the firm’s price target on Teva (TEVA) to $47 from $42 and keeps an Overweight rating on the shares as part of a Q3 earnings

2w agoTEVA

Salveen Richter Reiterates Buy on Teva, Sets $50 12-Month Target Backed by EV/EBITDA Valuation Ahead of Q3 Earnings

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Teva, with a price target of $50.00. Salveen Richter has given his Buy rating due to a combination of

2w agoTEVA

Teva price target raised to $50 from $40 at JPMorgan

JPMorgan raised the firm’s price target on Teva (TEVA) to $50 from $40 and keeps an Overweight rating on the shares. The company announced the approval of Weltruza with a

2w agoTEVA

Midday Fly By: SpaceX buys spectrum, Delta cuts earnings guidance

The major averages were broadly higher near noon as a rebound in tech stocks helps Wall Street bounce back. The major indexes are still on track for weekly gains, despite

3w agoT BA

Teva announces FDA approval for Weltruza

Teva (TEVA) announced that the FDA has approved Weltruza for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting injectable, or LAI, for the treatment of schizophrenia in adults. Weltruza clinical

3w agoTEVA

First Tracks Biotherapeutics price target raised to $62 from $55 at Wells Fargo

Wells Fargo raised the firm’s price target on First Tracks Biotherapeutics (TRAX) to $62 from $55 and keeps an Overweight rating on the shares. With Teva (TEVA) and Argenx (ARGX)

3w agoARGX TEVA

Teva call volume above normal and directionally bullish

Bullish option flow detected in Teva (TEVA) with 7,335 calls trading, 1.2x expected, and implied vol increasing over 2 points to 38.43%. Oct-26 40 calls and Oct-26 41 calls are

3w agoTEVA

Teva announces published review on dopamine pathways in Tourette syndrome

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced that the Journal of Child Neurology published a comprehensive review examining dopamine pathways in Tourette syndrome and the therapeutic

1M agoTEVA

Teva announces new data for ecopipam

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced new data for ecopipam. Presented at the International Congress of Parkinson’s Disease and Movement Disorders in Seoul, South Korea,

1M agoTEVA

Exxon Mobil downgraded, BP upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

1M agoBP ED

Teva, Samsung Bioepis expand strategic partnership to advance biosimilars

Samsung Bioepis and Teva (TEVA) Pharmaceutical Industries announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two

1M agoTEVA

Teva Rated Buy on Improving Balance Sheet, Emerging Pipeline, and Modest Upside to Current Share Price

Analyst Jason Gerberry of Bank of America Securities maintained a Buy rating on Teva, with a price target of $43.00. Jason Gerberry has given his Buy rating due to a

1M agoTEVA

Safe Pro Group (NASDAQ: SPAI) Draws WhaleWatchAlerts Attention Following Phillip Frost’s $4M Share Purchase

Austin, Texas, United States, September 15th, 2026, FinanceWire Billionaire investor Dr. Phillip Frost purchased 1 million restricted Safe Pro Group shares at $4 each and received the right to purchase

1M agoOPK SPAI

J.P. Morgan’s Salveen Richter Reiterates Buy on Teva, Citing TEV-408 Phase 2a Success and Pipeline-in-a-Product Potential

Teva Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Salveen Richter from Goldman Sachs maintained a Buy rating on the stock and has a

1M agoTEVA TEV

T1EV34 FAQ

What was Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR’s price range in the past 12 months?

Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR lowest stock price was $18.00 and its highest was $114.40 in the past 12 months.

What is Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR’s market cap?

Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR’s market cap is R$258.04B.

When is Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Is Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR pay dividends?

Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR does not currently pay dividends.

What is Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR’s EPS estimate?

Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR have?

Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR has 1,165,296,100 shares outstanding.

Which hedge fund is a major shareholder of Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR?

Currently, no hedge funds are holding shares in BR:T1EV34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR (T1EV34) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	15	4	3
Technical Analysis	3	4	3
Moving Averages	12	0	0

Technical Analysis >

Similar Stocks

Stocks similar to BR:T1EV34
Company	Price & Change	Follow
BR:A1LN34Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh
BR:B1DX34Becton, Dickinson and Company Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh
BR:B1ME34BeiGene Ltd ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR
BR:BIIB34Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs
BR:I1QV34IQVIA Holdings Inc Unsponsored Brazilian Depositary Receipt Repr 0.25 Sh

Compare BR:T1EV34 Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

T1EV34 Stock Chart & Stats

Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR News

Teva price target raised to $47 from $42 at Barclays

Salveen Richter Reiterates Buy on Teva, Sets $50 12-Month Target Backed by EV/EBITDA Valuation Ahead of Q3 Earnings

Teva price target raised to $50 from $40 at JPMorgan

Midday Fly By: SpaceX buys spectrum, Delta cuts earnings guidance

Teva announces FDA approval for Weltruza

First Tracks Biotherapeutics price target raised to $62 from $55 at Wells Fargo

Teva call volume above normal and directionally bullish

Teva announces published review on dopamine pathways in Tourette syndrome

Teva announces new data for ecopipam

Exxon Mobil downgraded, BP upgraded: Wall Street’s top analyst calls

Teva, Samsung Bioepis expand strategic partnership to advance biosimilars

Teva Rated Buy on Improving Balance Sheet, Emerging Pipeline, and Modest Upside to Current Share Price

Safe Pro Group (NASDAQ: SPAI) Draws WhaleWatchAlerts Attention Following Phillip Frost’s $4M Share Purchase

J.P. Morgan’s Salveen Richter Reiterates Buy on Teva, Citing TEV-408 Phase 2a Success and Pipeline-in-a-Product Potential

T1EV34 FAQ

Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR (T1EV34) Earnings & Revenues

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium